Effect of 5-LOX/COX-2 common inhibitor DHDMBF30 on pancreatic cancer cell Capan2

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 16

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

255

HTML

2463

Figures (1-5)

215

Tables (1-2)

193

Sum=3126

Apr 28, 2008 (publication date) through Aug 26, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Research

World J Gastroenterol. Apr 28, 2008; 14(16): 2494-2500
Published online Apr 28, 2008. doi: 10.3748/wjg.14.2494

Full Size Figure Download Figure

Figure 5 The VEGF expression of different group. A: Control group; B: DHDMBF30 group.

Citation: Zhang B, Wang CL, Zhao WH, Lv M, Wang CY, Zhong WX, Zhou WY, Yu WS, Zhang Y, Li S. Effect of 5-LOX/COX-2 common inhibitor DHDMBF30 on pancreatic cancer cell Capan2. World J Gastroenterol 2008; 14(16): 2494-2500
URL: https://www.wjgnet.com/1007-9327/full/v14/i16/2494.htm
DOI: https://dx.doi.org/10.3748/wjg.14.2494